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Effects of OKM5, a Monoclonal Antibody to Glycoprotein IV, on Platelet Aggregation and Thrombospondin Surface Expression
By Martha L. Aiken, Mark H. Ginsberg, Vicky Byers-Ward, and Edward F. Plow
The monoclonal antibody, OKM5. recognizes an 88-Kd monocyte membrane protein and also binds to the platelet membrane protein, GPIV (GPlllb, CD36). In this study, we have found that the OKM5 target epitope is present at approximately 12.000 copies per platelet and that interaction with the antibody has both stimulatory and inhibitory effects on platelet function. In the absence of other stimuli. OKM5 induced platelet aggregation, secretion, and expression of fibrinogen receptors. These stimulatory responses required intact antibody as F(ab'), fragments were not active but blocked the stimulatory activity of the intact antibody. In contrast, exposure of platelets to OKM5 followed by another strong stimulus such as thrombin resulted in a marked suppression of fibrinogen, fibronectin.
ONOCLONAL antibodies (MoAbs) have been used M extensively to examine the structure and function of platelet membrane glycoproteins.'.' The predominant targets of such MoAbs have been GPIb and GPIIb-IIIa. While the vast majority of described MoAbs to these or other platelet membrane proteins have inhibited platelet responses, a small number of reports have also described antibodies that activate platelet^.^" The target antigens of these activating
MoAbs have been either the light chain of GPIIb' or a 23-Kd protein:' unrelated to GPIIb. In the present report, we describe an MoAb that activates platelets by reacting with a different target antigen. In addition, this same MoAb that initiates the classical platelet responses of aggregation and secretion, can also, under certain circumstances, inhibit other platelet functions. The MoAb exhibiting these properties is OKMS.
OKMS was initially described by Talle et a16 as an MoAb reacting with monocytes; and it was shown by immunoprecipitation that the MoAb recognized an 88-Kd membrane protein. OKMS was also reported to react with platelets, endothelial cells, and certain tumor cells.6-* On platelets, the target antigen exhibits the properties of GPIV:-" also designated CD36 or GPIIIb. Additional studies have identified several interesting functions for the OKM5 antigen. One intriguing set of data has indicated that the OKMS antigen is involved in mediating the adherence of malarial-infected erythrocytes to endothelial cells, as well as other cell A second function has been attributed to the OKM5 antigen on platelets; namely, GPIV has been implicated as a collagen receptor on platelets." Still a third set of data has suggested that GPIV is the platelet receptor for thrombospondin (TSP)?" a member of the platelet-adhesive protein family. This proposed function for GPIV originally was based on the observation that OKMS inhibited the platelet surface expression of TSP as reported by a radiolabeled polyclonal anti-TSP Fab fragment, and TSP interacted with immunopurified OKMS antigen.g Support for this latter function of GPIV was subsequently obtained in studies involving the purified membrane protein." However, it is of note that when CD36 was expressed in COS cells, these cells did not acquire TSP binding proper tie^.'^ Based on these analyses, the OKMS antigen appears to function in adhesive responses of platelets and other cells. In the present study, we have examined the stoichiometry and functional consequences of the interaction of OKM5 with platelets. The results indicate that this MoAb exerts multiple effects on platelets, suggesting a multifunctional role of its target antigen in platelet responses.
MATERIALS AND METHODS
OKMS ascites was obtained from Ortho Diagnostics Systems, Inc (Raritan, NJ), and three separate batches of this reagent were used during the course of these studies, including 10 mL of ascites (3503-15) provided by Dr Peter Kramer of Johnson and Johnson (Raritan, NJ). The MoAb was purified essentially as described by Ey et a1.I6 In brief, 3 mL of ascites fluid, diluted 1:l with 0.1 mol/L phosphate buffer, pH 8.0, was incubated for 18 hours with 6 mL of Protein-A-Sepharose (Pharmacia Fine Chemicals, Piscataway, NJ) with gentle agitation at 4OC. The resin was then washed with phosphate-buffered saline (PBS) at pH 7.3 to remove unbound material. The MoAb was eluted with 0.1 mol/L Na citrate, pH 4.5, and collected in 4-mL aliquots into 0.5 mL of 1.0 mol/L Tris, pH 8.0. The fractions containing the MoAb were pooled, treated with 0.5 mmol/L pamidinophenylmethyl-sulfonyl fluoride (Calbiochem, La Jolla, CA), and dialyzed against PBS. It was our experience that purified OKM5 frequently lost activity during storage due to aggregation and that a high concentration of bovine serum albumin (BSA) helped to stabilize the OKM5 purification and characterization.
From the Department of Biochemistry, University of Texas Health Science Center at Tyler; and the Committee on Vascular reagent. Therefore, most of the antibody was stored at -8OOC in 1.0% BSA, and only a portion was frozen without BSA for radiolabeling. The activity of OKM5 was routinely tested on the day of its use in a solid phase radiometric assay in which binding of OKM5 to platelets coated onto microwells was assessed as previously described for other platelet MoAbs.I7 OKM5 was detected by the binding of 1251-antimouse immunoglobulin G (IgG) at 0.5 pg/mL. Active OKM5 gave a signal of at least threefold above background in this assay at concentrations of 20 fmol/L. F(ab'), fragments of OKM5 were prepared by pepsin digestion of the antibody. OKM5, at 140 to 220 pg/mL in 1% BSA (spiked with a small amount of 'Z51-OKM5 to permit polyacrylamide analysis of the preparations), was dialyzed overnight into 0.2 mol/L NaCI, 0.2 mol/L sodium acetate, pH 4.0, and the pH was then adjusted to 4.0 with acetic acid. Pepsin (Sigma Chemical Co, St Louis, MO) was added to a final concentration of 30 pg/mL, and the mixture was incubated for 3 hours at 37OC, at which time the pH was adjusted to 7.0.
Fibrinogen (Fg), fibronectin (Fn), and von Willebrand factor (vWF) were purified from fresh human plasma. The purifications involved differential ethanol or ether precipitation for Fg, gelatin-Sepharose affinity chromatography for Fn, and gel filtration of cryo-precipitates for vWF. TSP was purified from fresh platelet concentrates. The physical and platelet binding characteristics of the radioiodinated and nonlabeled forms of each of these proteins as prepared by our laboratories have been previously described.I8-" The preparation of the polyclonal anti-Fg and the production and purification of F(ab'), fragments of this antibody have also been previously reported in detail." The MoAbs, TSPI-1 (a TSP antibody), and PMI-1 (a GPIIb antibody), were produced and isolated as previously reported.22 TSPI-3, an MoAb to TSP that does not cross-compete with TSPI-1, is of the IgG, subclass and was derived from the same fusion as TSPI-1. These MoAbs were purified by the same protocol as described for OKM5, but they did not exhibit the instability of OKM5, even in the absence of BSA.
Proteins were radiolabeled by a modified chloramine-T procedure to specific activities of 0.5 to 1.5 pCi/pg. Residual free iodine was removed from the adhesive proteins by dialysis against PBS. To remove the residual free iodine from the radiolabeled antibodies, including OKM5, the samples were gel filtered on PD-10 columns (Pharmacia), equilibrated in and eluted with PBS. The protein concentrations of the radiolabeled antibodies was determined from the original protein concentration of the unlabeled protein, based on Lowry protein determinations or by their absorbance at 280 nm, and the precipitability of the radioactivity in 15% trichloroacetic acid. The precipitability in 15% trichloroacetic acid of radiolabeled OKM5, as well as of the other radiolabeled proteins, exceeded 95%, and protein recoveries were typically greater than 90%.
Washed human platelets were isolated from the blood of healthy adult donors with the approval of our local Human Investigations Committee and the Department of Health and Human Services. In brief, 90 mL of fresh human blood, collected into acid-citrate-dextrose, was centrifuged in two steps, first to obtain platelet-rich plasma (PRP) and then to obtain a platelet pellet. The cells were resuspended and gel filtered on Sepharose CL-2B (2.5 x 8 cm) (Pharmacia). The washed platelets were collected, and the cells were counted electronically in a Coulter Counter Model Zf (Coulter Electronics, Inc, Hialeah, FL) or microscopically in a hemacytometer. In some experiments, the cells were fixed with paraformaldehyde before microscopic counting. For this purpose, paraformaldehyde was added to the platelet suspension at a final concentration of 0.5%. After 30 minutes at 22OC, an equal volume of 0.02 mol/L NH,Cl in 0.15 mol/L Tris, pH 7.2, was Other proteins.
Radiolabeling of proteins.
Platelets.
Ligand binding assays. 1251-radiolabeled antibodies or adhesive proteins were incubated with washed human platelets at cell concentrations ranging from 1 x lo7 to 4 x 108/mL in Tyrode's-BSA buffer, pH 7.4, supplemented with selected divalent ions as previously Following 30 to 60 minutes at 22OC, 50-pL aliquots of the cell suspension were layered on 20% sucrose, and the platelets were pelleted by a 2.5-minute centrifugation in a Beckman microfuge B (Beckman, Palo Alto, CA). The tips of the tubes were amputated, and the molecules associated per cell calculated based on the determined specific activities of the ligands. Binding isotherms were analyzed with the Ligand Computer Program26 as previously described in studies from our
Washed human platelets at a final concentration of 1 x 108/mL in Tyrode's-BSA buffer containing 1 mmol/L Ca2+ and Mg2+ were incubated at 37OC at a constant stirring rate of 1,000 rpm in a dual channel platelet aggregometer (Scienco, Inc, Morrisen, CO). Exogenous Fg was added at 0.1 mg/mL. Aggregation was initiated by addition of the stimulus. Aggregation studies were also performed in a I/* dilution of PRP with cells at 1 to 2 x 1O8/mL.
Platelet secretion. To quantitate the release of serotonin, PRP (-20 mL) was incubated with 150 pCi of 'H-serotonin (27.3 Ci/mmol/L; NEN Research Products, Boston, MA) for 60 minutes at 37OC. The platelets were then isolated by gel filtration and suspended at 1 x 108/mL in Tyrode's buffer containing 2 mmol/L Ca2+, 2 mmol/L imipramine, 300 nmol/L Fg, and the selected stimulus. After 30 minutes at 22OC, conditions which paralleled the ligand binding assays used in this study, aliquots were centrifuged through 20% sucrose. The pelleted cells were solubilized with 10 mL of Aquafluor (NEN) and counted with a Beckman LS 7500 B-counter (Beckman Instruments, Inc, Fullerton, CA). j3-thromboglobulin secretion was measured with a commercial radioimmunoassay (Amersham, Arlington Heights, IL). Washed human platelets at 2 x 108/mL were incubated with or without 20 nmol/L OKM5 for 5 minutes followed by the addition of other platelet stimuli to the samples. After 5 minutes, D-phenylalanyl-L-prolyl-L-arginine chloromethylketone (PPACK from Calbiochem), was added to the cells stimulated with thrombin. Following a 10-minute incubation at 22OC, the cells were placed on ice and fixed with cold 2% paraformaldehyde. After 30 minutes, the paraformaldehyde was neutralized with NH4C1, the platelets were pelleted by centrifugation, and the supernatants assayed for j3-thromboglobulin.
Analytical procedures. Polyacrylamide gel electrophoresis in sodium dodecyl sulfate (SDS-PAGE) was performed in the buffer system of LaemmLz7 When required for sample reduction, 1% 2-mercaptoethanol was used. Molecular weights were estimated from the electrophoretic mobilities of the test samples relative to those of protein standards. For quantitation of the intensity of autoradiographic bands, a Zeineh soft laser scanning densitometer equipped with an integrator was used. For molecular exclusion chromatography by high performance liquid chromatography (HPLC), a TSK 4000 column (0.75-X60 cm) was used. The column was equilibrated in PBS at pH 6.75 and run at 0.9 mL/min. Elution profiles were monitored at 280 nm or by collecting 1-minute fractions and testing them for the platelet aggregating activity. For OKM5, 45 pg of the antibody was applied to the column and the aggregating activity of the fractions was detected by added IO-pL samples to PRP.
Platelet aggregation.

RESULTS
Binding of OKMS to platelets.
To assess the direct interaction of OKM5 with platelets, purified OKM5 was radioiodinated to a specific activity of approximately 1. SDS-PAGE. Under both reducing and nonreducing conditions, '251-OKMS and nonlabeled OKM5 exhibited the same electrophoretic properties. In preliminary experiments, the radiolabeled antibody was found to bind rapidly to platelets; apparent equilibrium binding was observed within 5 minutes, and the extent of binding did not change for at least 60 minutes. When varying quantities of '251-OKMS were added to washed human platelets, saturable binding of OKMS to both resting and stimulated platelets was observed at approximately 10 nmol/L (Fig 1) . At a saturating concentration of '251-OKMS, a fivefold excess of nonlabeled OKM5 inhibited binding of the radiolabeled ligand by greater than 80%. Data such as those shown in Fig 1 were analyzed with the Ligand Computer Program,26 and binding parameters derived for nonstimulated and thrombin-stimulated platelets in the presence or absence of divalent ions are summarized in Table 1 . The nonsaturable binding, N l , was extremely low; and, as it did not exceed 0.1% of total added 1251-OKMS radioactive under all conditions, subtraction of nonspecific binding was not necessary to see clear evidence of saturation of binding (see Fig 1) . For example, at a IO-nmol/L input concentration, 8,500 molecules of 1251-OKMS were bound per platelet of which 320 molecules were nonspecifically associated. The mean number of OKM5 binding sites per platelet under all experimental conditions was 1 1,900 f 1,800. Platelet stimulation and/or divalent ion conditions had only a minimal influence on the number of binding sites. From the apparent kd values listed in Table 1 , it is clear that OKMS bound to both stimulated and resting platelets with high affinity, and the interaction was not affected by divalent ion availability. Thrombin stimulation increased the apparent kd of the interaction slightly. The binding of '251-OKMS to platelets was not inhibited by large excesses of TSPI-3 or PMI-1, two MoAbs of the same subclass as OKMS, whereas it was inhibited by nonlabeled OKM5 derived from three different lots of the antibody. OKMS, at 20 nmol/L, was added to platelets at 1 x 108/mL in the presence of 300 nmol/L Fg and 1 mmol/L Ca2+ and Mg2+. After a short lag phase of approximately 2 minutes, an increase in light transmittance was observed in a platelet aggregometer, consistent with an aggregation or agglutination response. A classical platelet stimulus, adenosine diphosphate (ADP), induced aggregation of the same preparation of platelets without a detectable lag phase (Fig 2) . The response induced by 20 nmol/L OKMS was completely blocked by addition of EDTA (5 mmol/L), PGE, (1 pg/mL) and theophylline (1 mmol/L), the arginyl-glycyl-aspartyl-serine tetrapeptide (0.5 mmol/L), and the ADP scavenger system of creatine phosphate (12.7 mg/mL)/creatine phosphokinase (SO pg/mL). All of these agents inhibited Fg-dependent platelet aggregation induced by ADP and low concentrations of other platelet agonists such as epinephrine and t h r~m b i n ,~~. *~ but are known not to effect platelet agglutination such as in response to ristocetin. OKMS also aggregated platelets in plasma in the same dose range as it was active with washed platelets. However, in plasma the inhibition by ADP scavengers could be overcome by a further increase (fivefold) in OKM5 concentration. The existence of ADP-dependent and independent pathways for platelet aggregation is also noted for many platelet agonists.29
The capacity of OKM5 to induce a platelet secretory response was also examined. Serotonin and B-thromboglobulin were used to monitor dense and a granule secretion, respectively. As shown in Table 2 OKM5 was similar to that obtained with 0.25 U/mL thrombin. ADP caused only modest a and dense granule secretion; but, when added in combination with OKM5, extensive secretion was observed.
To further assess the ability of OKM5 to stimulate platelets, its capacity to induce Fg receptors was examined. Addition of 20 nmol/L OKM5 to resting platelets resulted in an increase in 12'I-Fg binding to the cells (Table 3 ). The extent of Fg binding induced by OKM5 was similar to that supported by ADP and thrombin. PGE, and theophylline inhibited Fg binding induced by OKM5.
To investigate the basis for the stimulatory activity of OKM5, F(ab'), fragments of the antibody were prepared. Densitometric scanning of SDS-PAGE established that greater than 75% of the intact antibody was digested to a 105-Kd F(ab')* fragment. While 20 nmol/L intact OKM5 induced aggregation of washed platelets, a fivefold higher concentration of the F(ab')* fragments did not (Fig 3) . Moreover, the antibody fragments blocked the capacity of the intact antibody to induce platelet aggregation. This effect was specific as the platelets retained their capacity to respond to ADP. BSA in buffer, exposed to the same protocol used to prepare the OKM5 F(ab'), fragments, did not block OKM5- PRP was incubated with 3H-serotonin for 1 hour at 37°C and the platelets were then isolated by gel filtration. The washed cells were incubated with prostaglandin E, (PGE,) and theophylline, at 1 pg/mL and 1 mmol/L, respectively, 20 nmol/L OKM5, 0.25 U/mL thrombin, 10 pmol/L ADP, or a combination of these reagents in the presence of 2 mmol/L Ca'+ and 2 pmol/L imipramine. After 10 minutes, the cells were centrifuged through 20% sucrose, and the cell pellet was solubilized and counted to determine the percent serotonin release. j3-thromboglobulin secretion was measured by radioimmunoassay. Washed human platelets at 2 x 108/mL were incubated with the same reagents indicated above.
After 10 minutes, the cells were placed on ice and fixed with 2% paraformaldehyde for 30 minutes (see Materials and Methods) . The cells were then pelleted by centrifugation, and the supernatants were assayed for 8-thromboglobulin by radioimmunoassay. Percent secretion is calculated relative to a sample of lysed platelets, which contained 26.4 pg 8-thromboglobulinll O9 cells.
Abbreviation: ND, not determined in this experiment. (In a separate experiment, the combination of OKM5 + thrombin produced 8% greater j3-thromboglobulin release than OKM5 alone, and 27% greater release than thrombin alone).
induced platelet aggregation. When OKM5 was subjected to the protocol, except that the pepsin was omitted, the aggregating activity of the antibody was retained. The requirement for intact antibody was also shown for induction of Fg binding. In an experiment in which 5 nmol/L intact OKM5 induced the binding of 4,600 Fg molecules per platelet, 100 nmol/L F(ab'), fragments supported the binding of only 900 Fg molecules, very similar to the level of 700 Fg molecules bound per platelet without any added stimulus.
To determine if the stimulatory activity of intact OKM5 was a function of the monomeric antibody, OKM5 was subjected to HPLC analysis on a TSK 4000 molecular exclusion column and 1 .O-minute fractions were collected. use only.
For personal at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From Platelet aggregatory activity eluted in the fractions from 19.0 to 23.0 minutes, coinciding to the elution position of a control MoAb, TSPI-1 (protein peak at 20.2 minutes). No platelet aggregation activity was detected in fractions eluting before 18.0 minutes. Fg, with a molecular weight of 340 Kd, eluted with a peak at 14.7 minutes, establishing that the 19.0-to 23.0-minute range was not the void volume of the column. Thus, the platelet stimulatory activity of OKM5 was not dependent on aggregates of the antibody.
Efects of OKM5 on the interaction of adhesive proteins with the platelet surface. In the course of experiments to assess the effects of OKM5 in combination with other platelet stimuli on 1251-Fg binding to platelets, unanticipated results were obtained. Namely, Fg binding did not occur when both OKM5 and thrombin were added to platelets. In these studies, OKM5 was preincubated with washed platelets before addition of thrombin. As shown in Fig 4 , Fg binding to thrombin-stimulated platelets was suppressed by OKM5; in a dose-dependent manner; and, at concentrations as low as 5 nmol/L, the inhibition exceeded 90%. Indeed, it should be noted that the inhibitory effect of OKM5 occurred in a dose range consistent with the estimated affinity of the antibody for platelets. The estimated kd of OKM5 for thrombin-stimulated platelets was 1.7 nmol/L (Table 1) and 12'I-Fg binding to thrombin-stimulated platelets was 50% inhibited by approximately 1 nmol/L OKM5 (Fig 4), showing a concordance between the binding of OKM5 to platelets and its inhibitory activity. Thus, the combination of OKM5 and thrombin abrogated the component of Fg binding induced by thrombin alone or by the antibody alone. In contrast, OKM5 concentrations as high as 22 nmol/L had no effect on ADP-induced Fg binding. As inhibition of TSP binding by OKM5 is predicted from the data of Asch et the capacity of the MoAb to influence the surface expression of endogenous TSP was also evaluated. In this analysis, the surface expression of TSP on thrombin-stimulated platelets was monitored with 12'I-TSPI-1,22 and 1251-Fg binding was measured in parallel. Divalent ion conditions were used to attain maximal surface expression for both ligands. Under these conditions, the stimulated cells bound 13,900 molecules of TSPI-1 (the divalent iondependent component of the measured TSP surface expression accounted for 68% of the total TSPI-1 binding22) and 29,000 molecules of Fg. As shown in Fig 5, OKM5 did not inhibit the surface expression of TSP at a concentration of 9 . - nmol/L, whereas Fg binding was fully inhibited by OKM5 in the same cell preparation. In similar experiments, but with fourfold higher platelet concentrations, TSP surface expression was variably inhibited by saturating concentrations of OKM5 (20 to 100 nmol/L). When inhibition was observed, it did not exceed 50%, and visible platelet aggregates were apparent. Under these circumstances, surface expression of platelet Fg, measured with "'I-F(ab'), fragments of an anti-Fg,*' was also inhibited.
The above observations suggest that platelet aggregation contributes to the effects of OKM5 on the interaction of exogenous or endogenous adhesive proteins with the cell surface. Therefore, we determined if aggregate formation paralleled the differential effects of the MoAb on Fg binding induced by thrombin, PMA, and ADP. Platelets were incubated with 20 nmol/L OKM5 or buffer for 5 minutes before addition of thrombin, ADP, or PMA. Nonlabeled Fg was present at 300 nmol/L to duplicate the experiments in which the binding of 12'I-Fg was measured. After 30 minutes, the cells were fixed with paraformaldehyde and observed microscopically to determine the number of single versus aggregated platelets per sample ( Table 4) . Cell suspensions stimulated with thrombin in the presence of OKM5 exhibited a significant decrease in single platelets as compared with cells stimulated with thrombin alone. In addition to this marked decrease in free platelets, the aggregates themselves were massive (Fig 6) , containing large numbers of platelets. These changes were not observed with ADP-stimulated cells, and an intermediate response was observed with PMA. In parallel with nonfixed cells, OKM5 inhibited the binding of Fg by 87% to thrombin-stimulated cells, 0% to ADPstimulated cells, and 55% to PMA-stimulated cells. Thus, in all samples exhibiting an inhibition of "'I-Fg binding by OKM5, there was also a marked increase in aggregate formation as reflected by a decrease in the number of single platelets. Other combinations of agonists did not have the Because platelet aggregation should be less extensive at low cell concentrations, the ability of OKM5 to inhibit thrombin-induced Fg binding was assessed as a function of cell concentration. The results of these analyses are summarized in Table 5 were treated first with OKM5 and then with thrombin, the condition that resulted in greater than 90% inhibition of Fg binding, most of the platelets were aggregated, and the aggregates were massive. In contrast, when the platelets were treated first with thrombin followed by the simultaneous addition of OKM5 and Fg, the condition at which the inhibition of Fg binding was less extensive, platelet aggregation was also considersbly less extensive.
The effect on Fg binding of F(ab'), fragments of OKM5, which, as shown above, do not induce platelet aggregation, was tested. With thrombin-stimulated (0.1 U/mL) platelets, 32,900 + 1,000 Fg molecules were bound per platelet at an input concentration of 300 nmol/L Fg. OKM5, at a 20 nmol/L concentration reduced Fg binding to 4,700 * 100, an 86% inhibition. In contrast, the F(ab'), fragments, at a concentration as high as 100 nmol/L, did not inhibit Fg binding (36,700 5 1,050 Fg molecules/platelet).
DISCUSSION
The OKM5 antigen is expressed by a variety of cell^^-^;
and, on platelets, the antibody reacts with the membrane protein designated GPIV.9 Our analysis of the interaction of OKM5 with platelets provides a quantitative estimate of the density of GPIV. The number of OKM5 epitopes per platelet was estimated to be approximately 12,000. Assuming one epitope per GPIV, this membrane protein is present at to Y2 the abundance of GPIIb-IIIa and GPIb.
OKM5 can act as platelet stimulus. The antibody induced platelet aggregation, secretion, and expression of Fg binding sites, causing a response pattern similar to that induced by thrombin. That these effects were due directly to the antibody, and not a contaminating component within the OKM5 preparations, is shown by: (1) the low concentrations of OKM5 required to induce these effects; (2) the failure of other MoAbs, isolated by an identical protocol, to induce these effects; (3) the failure of protease inhibitors, including PPACK and p-amidinophenylmethyl-sulfonyl fluoride, to abrogate these effects; and (4) the capacity of F(ab'), fragments of OKM5 to selectively block the stimulatory activity of intact OKM5. The later results show that the Fc region of antibody is required for induction of platelet responses. As many antibodies to platelet antigens, including those of the same subclass as OKM5, such as PMI-I, do not stimulate platelets, engagement of the target antigen by the antibody combining site, as well as secondary Fc-dependent interactions, are required for platelet stimulation.
When thrombin-stimulated platelets were preincubated with OKM5, the capacity of these cells to bind "'I-Fg was markedly decreased. Thus, the combination of these two platelet agonists suppressed Fg binding induced by either agonist individually. The effect was observed at OKM5 concentrations consistent with the measured affinity of the antibody for the platelet. This effect was not due to neutralization of the thrombin as shown by the observations that: (1) thrombin retained its capacity to induce platelet secretion in the presence of OKM5 (Table 2) ; (2) thrombin activity measured with the synthetic substrate S2238 (Ortho Diagnostics) was not affected by OKM5 (data not shown); and (3) Fg binding induced by PMA was also inhibited by OKM5, use only.
For personal at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From although less extensively than with thrombin. OKM5 was not a general inhibitor of platelet stimulation as Fg binding to ADP-stimulated platelets was unaffected and the antibody itself could induce Fg binding in the absence of other stimuli. Moreover, these effects were not restricted to Fg binding, as vWF and Fn binding to thrombin or PMA-stimulated platelets were also affected. By direct examination, it was found that conditions under which OKM5 inhibited Fg binding to platelets also resulted in extensive platelet aggregate formation. Furthermore, when aggregation was less extensive, at lower platelet counts or by altering the order of thrombin and OKM5 addition, OKM5 produced minimal inhibition of Fg binding. Taken together, these observations suggest a strong correlation between the inhibition of Fg binding by OKM5 and its induction of aggregates within the platelet suspension. However, cell-cell contact cannot account entirely for the inhibition of Fg binding by OKM5. Platelet suspensions stimulated with thrombin also showed a reduced number of free platelets, but the extent of Fg binding to thrombin-stimulated platelets was independent of cell concentration. One difference in the platelets stimulated with thrombin alone or OKM5 alone and those treated with OKM5 + thrombin may reside in the massive size of the platelet aggregates formed. The massive aggregates may prevent access of Fg to its receptors or unoccupied Fg receptors may be downregulated on aggregated platelets.
The present study has shown that an MoAb reactive with a target antigen other than GPIIb-IIIa can inhibit the binding of adhesive proteins to platelets. We have previously demonstrated that MoAbs to GPIIb-IIIa can inhibit the binding of an adhesive protein to a receptor independent of GPIIb-IIIa; ie, binding of TSP to platelets does not appear to be mediated by GPIIb-IIIa.30-32 Nevertheless, certain MoAbs to GPIIbIIIa inhibit TSP binding to platelets.20s33 These observations suggest a close proximal relationship between the TSP receptor and GPIIb-IIIa, as suggested by L e~n g ,~~ and further emphasize the need for considerable caution in interpreting antibodies inhibition of receptor-ligand interactions. Finally, the differences in the data presented in this study with those presented by Asch et a19 require comment. In contrast to our results, these investigators found that OKM5 inhibited surface expression of TSP and concluded that the OKM5 antigen was the TSP receptor on platelets. We have previously found that TSP binds to platelets through two distinct mechanisms, a divalent ion-dependent and a divalent ion-independent pathway.20,22 The OKM5 antibody did not appear to interfere with either of these two pathways, as measured by binding of added TSP or surface expression of endogenous TSP. Other pathways for TSP surface expression may exist. TSP interacts with Fg with high affinity.35 Based on our data, such a pathway could be inhibited by OKM5 if the antibody induced extensive platelet aggregation. Finally, while our data raise questions regarding the mechanism by which OKM5 might inhibit TSP surface expression on platelets, they do not exclude a role of GPIV as a TSP receptor. A potential role of GPIV in TSP binding to platelets has recently been although TSP receptors unrelated to GPIV have now been identified on other cell type^.^^.^^
